Solvay earns $25M as obesity drug advances

Solvay will garner a $25 million payday from Bristol-Myers Squibb as it advances its obesity therapy, SLV319, into additional mid-stage trials. The experimental drug is a CB1 antagonist, blocking the cannabinoid type 1 receptor in order to reduce the body's demand for food.

- read the AFX report on Solvay

ALSO: Sanofi-Aventis hopes Acomplia, its anti-obesity drug, will be approved by the FDA on or around April 27, 2007. Report

Related Article:
Sanofi touts Phase IIIb Acomplia results. Report